BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.700
-0.120 (-6.59%)
Apr 17, 2025, 4:00 PM EDT - Market closed
BioXcel Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Cash & Equivalents | 29.85 | 65.22 | 193.73 | 232.97 | 213.12 | Upgrade
|
| Cash & Short-Term Investments | 29.85 | 65.22 | 193.73 | 232.97 | 213.12 | Upgrade
|
| Cash Growth | -54.23% | -66.33% | -16.84% | 9.31% | 557.25% | Upgrade
|
| Accounts Receivable | 0.13 | 0.07 | 0.25 | - | - | Upgrade
|
| Receivables | 0.13 | 0.07 | 0.25 | - | - | Upgrade
|
| Inventory | 0.68 | 1.99 | 1.99 | - | - | Upgrade
|
| Prepaid Expenses | 5.29 | 2.78 | 3.07 | 2.89 | 2.96 | Upgrade
|
| Other Current Assets | 1.44 | 2.08 | 3.84 | 0.96 | 0.98 | Upgrade
|
| Total Current Assets | 37.39 | 72.14 | 202.87 | 236.81 | 217.07 | Upgrade
|
| Property, Plant & Equipment | 0.86 | 1.47 | 2.06 | 2.54 | 2.78 | Upgrade
|
| Other Long-Term Assets | 0.09 | 0.09 | 0.93 | 0.09 | 0.09 | Upgrade
|
| Total Assets | 38.34 | 73.7 | 205.85 | 239.44 | 219.94 | Upgrade
|
| Accounts Payable | 15.99 | 13.65 | 10.23 | 4.68 | 3.98 | Upgrade
|
| Accrued Expenses | 5.78 | 13.15 | 22.18 | 11.39 | 6.93 | Upgrade
|
| Current Portion of Leases | 0.37 | - | - | - | - | Upgrade
|
| Current Income Taxes Payable | 0.09 | 0.12 | 0.08 | 0.3 | 0.7 | Upgrade
|
| Other Current Liabilities | - | 0.35 | 0.4 | 0.29 | 0.24 | Upgrade
|
| Total Current Liabilities | 22.23 | 27.27 | 32.9 | 16.67 | 11.84 | Upgrade
|
| Long-Term Debt | 102.51 | 100.6 | 93.05 | - | - | Upgrade
|
| Long-Term Leases | 0.07 | 0.44 | 0.79 | 1.11 | 1.4 | Upgrade
|
| Other Long-Term Liabilities | 6.63 | 1.91 | 2.34 | - | - | Upgrade
|
| Total Liabilities | 131.44 | 130.21 | 129.08 | 17.77 | 13.24 | Upgrade
|
| Common Stock | 0.05 | 0.03 | 0.03 | 0.03 | 0.02 | Upgrade
|
| Additional Paid-In Capital | 557.05 | 534.06 | 488.29 | 467.43 | 345.53 | Upgrade
|
| Retained Earnings | -650.2 | -590.6 | -411.55 | -245.79 | -138.86 | Upgrade
|
| Shareholders' Equity | -93.1 | -56.51 | 76.78 | 221.67 | 206.7 | Upgrade
|
| Total Liabilities & Equity | 38.34 | 73.7 | 205.85 | 239.44 | 219.94 | Upgrade
|
| Total Debt | 102.95 | 101.04 | 93.84 | 1.11 | 1.4 | Upgrade
|
| Net Cash (Debt) | -73.09 | -35.82 | 99.89 | 231.86 | 211.72 | Upgrade
|
| Net Cash Growth | - | - | -56.92% | 9.51% | 574.34% | Upgrade
|
| Net Cash Per Share | -28.83 | -19.67 | 57.05 | 140.67 | 156.23 | Upgrade
|
| Filing Date Shares Outstanding | 5.49 | 1.91 | 1.81 | 1.75 | 1.54 | Upgrade
|
| Total Common Shares Outstanding | 3.1 | 1.87 | 1.76 | 1.75 | 1.53 | Upgrade
|
| Working Capital | 15.16 | 44.88 | 169.97 | 220.15 | 205.22 | Upgrade
|
| Book Value Per Share | -30.01 | -30.21 | 43.64 | 126.76 | 135.44 | Upgrade
|
| Tangible Book Value | -93.1 | -56.51 | 76.78 | 221.67 | 206.7 | Upgrade
|
| Tangible Book Value Per Share | -30.01 | -30.21 | 43.64 | 126.76 | 135.44 | Upgrade
|
| Machinery | 0.78 | 0.78 | 0.79 | 0.74 | 0.63 | Upgrade
|
| Construction In Progress | - | - | - | 0.02 | 0.36 | Upgrade
|
| Leasehold Improvements | 1.2 | 1.2 | 1.18 | 1.13 | 0.65 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.